U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339566) titled 'Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis' on Dec. 19, 2025.
Brief Summary: Subjects who have signed the informed consent form will undergo examinations and assessments according to the inclusion/exclusion criteria specified in the trial protocol. After screening and successful enrollment, they will enter the treatment period. Dosing time points are (W0, W2, W4, W8, W12), with a subcutaneous injection of Xeligekimab 100mg each time. Week 12 is the last dosing time. After week 12, the physician will comprehensively assess whether to continue using Xeligekimab based on the patient'...